secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001104659-24-051581
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA announces pivotal Phase 2/3 trial design for HB-200 in combo with pembrolizumab; FDA alignment
--------------------------------------------------------------------------------

- Pivotal Phase 2/3 trial for HB-200 + pembrolizumab in first-line HPV16+ recurrent/metastatic OPSCC; FDA alignment achieved.
- Trial expected to enroll ~250 patients; Phase 2 primary analysis in 2026 with potential accelerated approval filing.
- First patient enrollment anticipated in Q4 2024.
- HB-200 abstract accepted as oral presentation at ASCO 2024 with data from ~40 patients in head and neck cancer.
- Company also received PRIME designation from EMA for HB-200 in combination with pembrolizumab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465924051581/0001104659-24-051581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465924051581/tm2412672d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-051581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer